🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to scientists.

A Global Challenge

Cases of gonorrhoea are escalating globally, with figures suggesting over 82 million infections each year. Particularly high rates are reported in the African continent and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the reality of growing infection rates, the spread of superbugs and the extremely scarce treatment choices currently available.”

Health officials are particularly alarmed about the surge in treatment-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program found that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Therapies Gain Authorization

One new antibiotic, marketed under the name a brand name, was authorized by the American regulatory agency in mid-December for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers anticipate that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, was also approved in concurrent days. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This milestone marks a significant shift in the management of superbug gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Research Study Outcomes and Worldwide Availability

As per data detailed in a prominent scientific publication, the new drug eradicated more than 90% of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which combines two antibiotics. The research involved hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the authority to register and commercialise the drug in many regions with limited resources.

Medical professionals on the front lines have voiced hope. Access to a one-pill regimen of this kind is hailed as a "critical tool" for gonorrhoea control. This is deemed essential to reduce the burden of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.